호산구성 식도염 시장 : 약제 클래스별, 유통 채널별, 지역별-2025-2032년 시장 규모, 점유율, 전망, 기회 분석

Global Eosinophilic Esophagitis Market is estimated to be valued at USD 239.1 Mn in 2025 and is expected to reach USD 1,797.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 33.4% from 2025 to 2032.

Figure. Eosinophilic Esophagitis Market Share (%), By Region 2025

Eosinophilic esophagitis is a chronic condition which is treated with the help of steroids and acid suppressants such as proton pump inhibitors. Steroids help control the inflammation. Topical steroids are administered as a inhaler or as a liquid. Oral steroids may be prescribed to treat people who have serious swallowing problems or weight loss. Proton pump inhibitors help with reflux symptoms and decrease inflammation.

Market Dynamics

Growing awareness regarding eosinophilic esophagitis leads to an increase in demand for treatment products. Thus, key market players are engaged in developing newer treatments and addressing the demand for EoE treatment products. For instance, Sanofi S.A. a global biopharmaceutical company engaged in conducting a phase 3 clinical trial for Dupixent (dupilumab) and is estimated to complete by 2024. Additionally, upcoming innovative products to improve the management of EoE are anticipated to drive the global market growth. For instance, in December 2021, Takeda Pharmaceutical Company Limited a Japanese multinational pharmaceutical company received a Complete Response Letter (CRL) for TAK-721 (budesonide oral suspension) from the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis. In June 2021, the U.S. FDA granted Orphan Drug Designation (ODD) for Etrasimod. Etrasimod had been investigated by Arena Pharmaceuticals, Inc. an American biopharmaceutical company. Moreover, an increase in the prevalence of eosinophilic esophagitis is likely boost the market growth. For instance, according to a study published in the Saudi Medical Journal in July 2018, eosinophilic esophagitis is an emerging disease and has an increasing incidence in children in Saudi Arabia.

Key features of the study:

• This report provides an in-depth analysis of the global eosinophilic esophagitis market size (US$ Mn), and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global eosinophilic esophagitis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, strategies
• Key companies covered as a part of this study include Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global eosinophilic esophagitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global eosinophilic esophagitis market

Detailed Segmentation:

• Global Eosinophilic Esophagitis Market, By Drug Class:
  • Corticosteroids
  • Budesonide
  • Jorveza
  • Off-label budesonide
  • Fluticasone
  • Proton Pump Inhibitor (PPI)
  • Omeprazole
  • Esomeprazole
  • Others
  • Late Stage Pipeline Drugs
  • Dupixent
  • APT-1011
  • Lirentelimab (AK002)
  • Cendakimab
  • Etrasimod
  • TAK-721
  • Omilancor (BT-11)
• Global Eosinophilic Esophagitis Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Eosinophilic Esophagitis Market, By Region:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles
  • GlaxoSmithKline plc
  • Ellodi Pharmaceuticals
  • EsoCap AG
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Sun Pharmaceutical Industries Limited
  • AstraZeneca Plc
  • Sanofi S.A.
  • Arena Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Revolo Biotherapeutics
  • Allakos Inc.
  • Bristol-Myers Squibb Co
  • Calypso Biotech
  • DBV Technologies
  • Landos Biopharma, Inc.
  • Glenmark Pharmaceuticals
  • Alkem Laboratories Ltd.
  • Quorum Innovations LLC
  • Dr. Falk Pharma GmbH

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Drivers
• Restraints
• Opportunities
• Impact Analysis
• Pipeline Analysis
• Regulatory Scenario
• Recent Product Approval/Launch
• PEST Analysis
• Epidemiology

4. Global Eosinophilic Esophagitis Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply and Demand Analysis
• Key Developments

5. Global Eosinophilic Esophagitis Market, By Drug Class, 2020 - 2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Corticosteroids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
    • Budesonide
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
        • Jorveza
          • 1. Introduction
          • 2. Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
        • Off-label budesonide
          • 1. Introduction
          • 2. Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
    • Fluticasone
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
• Proton Pump Inhibitor (PPI)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
    • Omeprazole
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
    • Esomeprazole
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
• Late Stage Pipeline Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
    • Dupixent
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
    • APT-1012
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
    • Lirentelimab (AK002)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
    • Cendakimab
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
    • Etrasimod
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
    • TAK-721
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
    • Omilancor (BT-11)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)

6. Global Eosinophilic Esophagitis Market, By Distribution Channel, 2020 - 2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)

7. Global Eosinophilic Esophagitis Market, By Region, 2020 - 2032, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2029 (%)
  • Y-o-Y Growth Analysis, For Regions, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Heat Map Analysis
• Market Share Analysis
  • Ellodi Pharmaceuticals.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Strategies
  • EsoCap AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Strategies
  • GlaxoSmithKline plc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Teva Pharmaceutical Industries Ltd
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Cipla Limited
  • Sun Pharmaceutical Industries Limited
  • AstraZeneca Plc
  • Sanofi S.A.
  • Arena Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Revolo Biotherapeutics
  • Allakos Inc.
  • Bristol-Myers Squibb Co
  • Calypso Biotech
  • DBV Technologies
  • Landos Biopharma, Inc.
  • Glenmark Pharmaceuticals
  • Alkem Laboratories Ltd.
  • Quorum Innovations LLC
  • Falk Pharma GmbH

9. Analyst Recommendation

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. Section

• References
• Research Methodology
• About Us and Sales Contact